| Nov 14 |
Oruka Therapeutics files to sell 8.72M shares of common stock for holders
|
| Nov 13 |
Oruka Therapeutics GAAP EPS of -$1.46 misses by $1.08
|
| Nov 13 |
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
| Nov 4 |
Oruka Therapeutics to Present at Multiple November Investor Conferences
|
| Sep 25 |
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress
|
| Sep 12 |
Oruka Therapeutics announces $200M private financing
|
| Sep 12 |
Oruka Therapeutics Announces $200 Million Private Placement
|
| Sep 12 |
Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19
|
| Sep 3 |
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
|
| Aug 29 |
ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split
|
